HP Donates D300e BioPrinters to NGOs, Universities, and Research Institutions to Accelerate Drug and Vaccine Research to Comb...
13 Juli 2020 - 02:00PM
HP Inc. (NYSE: HPQ) today announced the deployment of HP D300e
BioPrinters, associated supply cassettes, and training, free of
charge, to research laboratories in the U.S. and Europe to help
accelerate drug and vaccine research to combat COVID-19.
“Each of us has a role to play to combat this
pandemic, and HP and the HP Foundation have donated millions of
dollars in products and grants to support local communities
impacted by COVID-19 worldwide,” said Annette Friskopp, Global Head
and General Manager, Specialty Printing Systems, HP Inc. “We are
inspired by the research being conducted by laboratories worldwide
to better understand this pandemic, and if the HP D300e BioPrinter
in the hands of these scientists can help accelerate their drug and
vaccine research, it’s our responsibility to step forward and
dedicate resources and technology to make it happen.”
How it worksThe BioPrinter with
inkjet printing technology enables automated laboratory dispensing
to “print” pharmaceutical samples instead of ink. The BioPrinter
accurately dispenses or “prints” volumes from picoliters to
microliters for fast, reliable dispensing of small molecules and
biomolecules. The BioPrinter enables labs to eliminate serial
dilution from dose response workflows, miniaturize qPCR reaction
volumes, and easily dispense any volume in any well for a broad
array of low-volume dispensing applications in drug discovery,
genomics, and proteomics research.
Spanish National Research Council (CSIC), the
largest and leading public research institution in Spain, will
leverage the BioPrinter to investigate how the spike protein of
COVID-19 reacts in the population most at risk for infection,
including healthcare professionals, security forces, and the
elderly. The Madrid-based institution will also contribute to the
research of new drugs capable of controlling the interaction of the
ACE2 receptor for the protein S of COVID-19, the main gateway for
the virus; and map the SARS-COV-2 "peak" protein using different
fragments and epitopes of proteins, among others.
Researchers from the Center for Nuclear Receptors
and Cell Signaling (CNRCS) at University of Houston are developing
anti-viral drugs and prophylactic vaccines for COVID-19. In
particular, efforts to develop an innovative drug screening
platform for the virus are in progress. This high-throughput
screening system can be easily modified for other infectious
diseases. The BioPrinter will be used to dispense reagents with
high accuracy and develop a drug development tool for COVID-19
treatment.
Monoclonal Antibody Discovery Laboratory at
Fondazione Toscana Life Sciences in Siena, Italy focuses on
monoclonal antibody (mAb) discovery against infectious diseases.
The lab will use the BioPrinter will accelerate their testing of
potency of mAbs against COVID-19, as well as other infectious
bacteria and viruses.
Grenoble Alpes University Hospital (CHUGA), the
third largest research university in France, released emergency aid
to a team of scientists and doctors to launch bio-clinical research
on COVID-19 immunization. The BioPrinter will be used to automatize
the screening of infected individuals' sera for neutralizing
antibodies.
COVID-19 community responseHP and
HP Foundation have committed to donate an estimated $8 million
worth of technology and grants to support blended learning and
local communities impacted by COVID-19 worldwide. HP and its global
network of partners and customers have also produced more
than 3.3 million 3D printed parts for face shields,
respirators, nasal swabs and other items for distribution to
hospitals.
Learn moreVisit the following
links for more details:
- HP’s Response to COVID-19 Online Press Kit
- HP D300e BioPrinter Online Press Kit
- HP Life Sciences Dispensing Website
- A Message from HP CEO Enrique Lores
About Microfluidics at HPHP Inc.
is the world leader in fluidic based micro Electro-Mechanical
Systems (MEMS) devices embodied in inkjet printing today.1 HP has
invested billions of dollars in research and development, as well
as capital equipment over the past three decades to create the
world’s largest digital printing company. All this provides the
foundation to extend this technology into new domains. HP’s
Specialty Printing Systems (SPS) and the Microfluidics Technology
and Operations (MTO) teams have collaborated to bring HP’s first
life science application in this space to market: The HP D300e
BioPrinter with inkjet printing technology is enabling automated
laboratory dispensing to “print” pharmaceutical samples instead of
ink. The BioPrinter is being used by labs and pharmaceutical
companies all over the world, including the Centers for Disease
Control & Prevention (CDC) in the Antibiotic Resistance (AR)
Lab Network, to perform antimicrobial susceptibility testing for
health departments and hospitals nationwide. Learn more:
http://www.hp.com/go/bioprint.
About HPHP Inc.
creates technology that makes life better for everyone, everywhere.
Through our product and service portfolio of personal systems,
printers and 3D printing solutions, we engineer experiences that
amaze. More information about HP Inc. is available at
http://www.hp.com.
Lacey Haines, HPlacey.haines@hp.comhp.press.ext
©Copyright 2020 HP Development Company, L.P. The
information contained herein is subject to change without notice.
The only warranties for HP products and services are set forth in
the express warranty statements accompanying such products and
services. Nothing herein should be construed as constituting an
additional warranty. HP shall not be liable for technical or
editorial errors or omissions contained herein.
1 Based on device revenue as reported in the Yole
Développement Status of the MEMS Industry Report, 2019.
Photos accompanying this announcement are
available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/3c643a01-e7e8-4fea-b914-4dbaca178afahttps://www.globenewswire.com/NewsRoom/AttachmentNg/50bffbdd-a4e6-44a6-88d2-1dcb032e0b60
HP (NYSE:HPQ)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
HP (NYSE:HPQ)
Historical Stock Chart
Von Mär 2023 bis Mär 2024